In recent decades, the incidence of some hematological malignancies (HMs), such as acute lymphocytic leukemia (ALL) and chronic myeloid leukemia (CML), has decreased, while the incidence of others ...

CAR T cell therapy has revolutionized cancer treatment, achieving significant success in hematological cancers through ...

Three patients also had a complete remission but without higher white blood cell counts, known as a complete remission with ...

The primary challenge for next-generation CAR-T therapy is its effectiveness in treating solid tumors [8,9]. Currently, CAR-T ...

Good day, and welcome to the Bionano third quarter 2024 earnings conference call. Today's conference is being recorded. At this time, I would like to turn the conference over to David Holmes from ...

T-cell therapy is a revolutionary immunotherapy approach in which T cells are genetically modified to express a receptor that ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

Our growing volume of in vitro and in vivo data support the potential to deliver broadly effective and safe cancer therapies that can overcome the shortcomings of currently marketed therapeutics by ...

(RTTNews) - Syndax Pharmaceuticals, Inc. (SNDX), Tuesday announced positive results from the relapsed or refractory mutant NPM1 acute myeloid leukemia cohort in the pivotal Phase 2 portion of the ...

Syndax Pharmaceuticals announces positive Phase 2 trial results for revumenib in relapsed/refractory mNPM1 AML, with key ...

Dr. Zachery Oestreicher is a co-author. Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed ...

Syndax (SNDX) announced positive topline results from the relapsed or refractory mutant NPM1 – mNPM1 – acute myeloid leukemia, or ...